SGMO earnings call for the period ending March 31, 2019.
News & Analysis: Sangamo Therapeutics
The biopharma announced first-quarter 2019 operating results.
The biotech's revenue fell. But it still managed to beat the consensus Wall Street earnings estimate.
The grandaddy of gene-editing stocks recently provided an encouraging update, but it isn't the only experimental hemophilia therapy out there.
Some investments stood out on a quiet day for the market.
Promising early clinical data has investors excited about Sangamo's hemophilia A gene therapy.
Which of these gene editing stocks will come out on top?
The future of treating disease might be gene editing, and these five stocks have the most promising technologies.
The company offered up more disappointing data for its zinc-finger gene-editing platform.
SGMO earnings call for the period ending December 31, 2018.